BioCity Biopharmaceutics Co., Ltd. Announces Clinical Collaboration to Evaluate BC3195 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Locally Advanced or Metastatic Solid Tumors
SHANGHAI, March 13, 2025 /PRNewswire/ -- BioCity Biopharmaceutics Co., Ltd., a clinical-stage biopharmaceutical company, today announced that it has entered into a clinical trial collaboration agreement with MSD (Merck & Co., Inc., Rahway, NJ, USA), to evaluate the combination of BioCity's BC3195 and MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in a global phase 1/2 trial in patients with locally advanced or metastatic...
Ping An Health Reports First Full-Year Profit in 2024
Synergies Between Health Care and Insurance Drive Scalable GrowthAI Innovations Fuel Continued Success SHANGHAI and HONG KONG, March 13, 2025 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor", "Ping An Health" or "the Company", Stock Code: 1833.HK) announced its 2024 annual results. With a strategic focus on its two core service hubs - family doctors...
Caliber Launches 4 Analytics and AI-driven Solutions to Revolutionize Pharma Manufacturing and Quality
PITTSBURGH, March 13, 2025 /PRNewswire/ -- Caliber recently launched 4 digital solutions that further strengthen its portfolio and also position the company at the forefront of the Pharma 4.0 revolution. These innovations integrate AI and next-gen technologies, reinforcing Caliber's commitment towards preparing the life sciences industry for the future with holistic digital...
GC Cell Initiates First Patient Dosing in Phase 1 Clinical Trial for GCC2005, a Promising T‑Cell Lymphoma CD5 CAR-NK Therapy
YONGIN, South Korea, March 13, 2025 /PRNewswire/ -- GC Cell (KRX:144510), under the leadership of CEO Sungyong Won, announced today the initiation of its domestic Phase 1 clinical trial for GCC2005 (AB‑205), a novel CD5 CAR‑NK cell therapy. This "first patient dosing" marks a critical milestone in the company's collaboration with its...
STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), now available in the United States
STEQEYMA®, one of the first-wave biosimilars to STELARA®, is now available in the U.S. Approved for the same indications as the reference product, STEQEYMA will be priced with a wholesale acquisition cost (WAC) list price at an 85% discount to the current WAC list price of STELARA to help improve patient...
Telix Adds Lead-212 Isotope Production Capability
MELBOURNE, Australia and INDIANAPOLIS, March 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that it has developed and validated a breakthrough generator technology for the production of lead-212 (212Pb) and successfully completed first production. The new generator technology, developed internally by Telix's IsoTherapeutics team, produces...
Carbon to Unveil Expanded AO Suite, New Parts Retrieval Basket, and Industry-Shaping Innovations at IDS 2025
New automation solutions and material advancements aim to streamline workflows and expand possibilities for dental labs COLOGNE, Germany, March 12, 2025 /PRNewswire/ -- Carbon, a global leader in 3D printing for digital dentistry, will showcase its latest innovations at IDS 2025 in Cologne (Hall 3.1, Stand L009), highlighting advancements in automation, material development, and workflow optimization for dental labs....
111, Inc. to Participate in Fireside Chat with Water Tower Research on March 26, 2025
SHANGHAI, March 12, 2025 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced that it will participate in a fireside chat with Robert Sassoon, senior research analyst at Water Tower Research ("WTR") on Wednesday,...
Waterdrop Inc. Announces Fourth Quarter and Fiscal Year 2024 Unaudited Financial Results and a Cash Dividend
BEIJING, March 12, 2025 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced its unaudited financial results for the three and twelve months ended December 31, 2024 and a cash dividend. Financial and Operational Highlights for the Fourth Quarter of...
Pierre Fabre Laboratories and RedRidge Bio Announce a Drug Discovery and Co-development Partnership
CASTRES, France, CAMBRIDGE, Massachusetts and BASEL, Switzerland, March 12, 2025 /PRNewswire/ -- Pierre Fabre Laboratories and RedRidge Bio ("RedRidge") today announced an exclusive R&D collaboration and license agreement to identify and develop biparatopic antibody (BPA) drug candidates against multiple targets. In line with Pierre Fabre Laboratories' innovation strategy, the partnership's therapeutic focus will be...
